REFERENCES
1. Sahin M, Sur M. Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science 2015;350:aab3897.
2. Vissers LE, Gilissen C, Veltman JA. Genetic studies in intellectual disability and related disorders. Nat Rev Genet 2016;17:9-18.
3. Akbarian S, Nestler EJ. Epigenetic mechanisms in psychiatry. Neuropsychopharmacology 2013;38:1-2.
4. Chase KA, Rosen C, Rubin LH, Feiner B, Bodapati AS, Gin H, Hu E, Sharma RP. Evidence of a sex-dependent restrictive epigenome in schizophrenia. J Psychiatr Res 2015;65:87-94.
5. Houtepen LC, van Bergen AH, Vinkers CH, Boks MP. DNA methylation signatures of mood stabilizers and antipsychotics in bipolar disorder. Epigenomics 2016;8:197-208.
6. Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 2013;38:124-37.
7. Cerase A, Pintacuda G, Tattermusch A, Avner P. Xist localization and function: new insights from multiple levels. Genome Biol 2015;16:166.
8. Pintacuda G, Young AN, Cerase A. Function by structure: spotlights on Xist long non-coding RNA. Front Mol Biosci 2017;4:90.
9. Pinter SF. A tale of two cities: how Xist and its partners localize to and silence the bicompartmental X. Semin Cell Dev Biol 2016;56:19-34.
10. Franco B, Ballabio A. X-inactivation and human disease: X-linked dominant male-lethal disorders. Curr Opin Genet Dev 2006;16:254-9.
11. Cantone I. Reversal of X chromosome inactivation: lessons from pluripotent reprogramming of mouse and human somatic cells. J Transl Genet Genom 2017;1:1-14.
12. Przanowski P, Waśko U, Bhatnagar S. Novel molecular players of X chromosome inactivation: new technologies and new insights. J Transl Genet Genom 2018;2:2.
